1500009L16Rik Inhibitors
Chemical inhibitors of 1500009L16Rik can interfere with its function by targeting various signaling pathways that regulate the activity of this protein. Wortmannin and LY294002 are examples of such inhibitors, both of which target the phosphatidylinositol 3-kinase (PI3K) pathway. By inhibiting PI3K, these chemicals prevent the phosphorylation and activation of downstream proteins, including AKT, ultimately leading to the functional inhibition of 1500009L16Rik. Rapamycin follows a different route, binding to mTOR to inhibit its activity within the mTOR signaling pathway. As 1500009L16Rik relies on signals propagated through mTOR, its activity is consequently suppressed in the presence of rapamycin.
Continuing along the signaling cascade, U0126 and PD98059 function by inhibiting MEK1/2, which are essential components of the MAPK/ERK pathway. This inhibition results in the functional suppression of 1500009L16Rik if it is regulated by this particular pathway. Similarly, SB203580 and SP600125 target other kinases in the MAPK family, namely p38, and JNK, respectively. By inhibiting these kinases, SB203580 and SP600125 can decrease the functional activity of proteins like 1500009L16Rik that are downstream of these signaling molecules. Furthermore, gefitinib, erlotinib, and lapatinib block the EGFR signaling pathway, which can also lead to the functional inhibition of 1500009L16Rik if it is a downstream effector of EGFR signaling. Additionally, sorafenib's broad-spectrum kinase inhibition can suppress various pathways potentially governing the activity of 1500009L16Rik. Lastly, triciribine directly inhibits AKT, another key molecule in the AKT/mTOR signaling pathway, leading to the functional inhibition of 1500009L16Rik, demonstrating the interconnected nature of these signaling networks and their influence on protein function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphatidylinositol 3-kinase (PI3K), which is involved in the PI3K/AKT signaling pathway. Inhibition of this pathway can lead to the functional inhibition of 1500009L16Rik by preventing its activation or downstream signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor that can impede the PI3K/AKT pathway, thereby inhibiting the activation of downstream proteins including 1500009L16Rik by preventing phosphorylation events that are critical for its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin selectively binds to mTOR and inhibits its activity, which is a part of the mTOR signaling pathway. This inhibition can lead to decreased activity of downstream proteins such as 1500009L16Rik, which rely on mTOR signaling for their function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 acts as an inhibitor of MEK1/2, critical components of the MAPK/ERK pathway. By inhibiting MEK1/2, U0126 can lead to the functional inhibition of 1500009L16Rik if it relies on MAPK/ERK signaling for its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. Inhibition of p38 MAPK can result in diminished downstream signaling, which can functionally inhibit proteins like 1500009L16Rik that are part of or dependent on this pathway for their activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, and by inhibiting JNK, it can reduce the activity of proteins associated with the JNK signaling pathway. This can functionally inhibit 1500009L16Rik if it is regulated by or associated with JNK-mediated signaling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR inhibitor that can block the EGFR signaling pathway. By doing so, it can functionally inhibit downstream proteins like 1500009L16Rik that may require EGFR signaling for their functional activity. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib, another EGFR tyrosine kinase inhibitor, can functionally inhibit the EGFR pathway, leading to decreased activity of proteins like 1500009L16Rik if they are downstream effectors of EGFR signaling. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib targets both EGFR and HER2/neu receptors, leading to inhibition of their associated signaling pathways. This inhibition can functionally suppress the activity of proteins such as 1500009L16Rik that are part of these pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib inhibits multiple receptor tyrosine kinases involved in various signaling pathways. As a multi-kinase inhibitor, it can functionally inhibit 1500009L16Rik by blocking the signaling cascades that contribute to its activity. | ||||||